Regulatory GSK again pulls application for leucovorin, touted by FDA as potential autism treatment BioSpaceGSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to...RegulatoryNeuroscienceRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioSpace GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to… RegulatoryNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche places a $1bn bet on C4T degrader-antibody conjugatesNext: Senju launches first-in-class dry eye disease drug in Japan Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
